Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?

Alessandro Leonetti^{1

2}, Francesco Facchinetti³, Marcello Tiseo^{1

4}

Affiliations

¹ Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
² Department of Medical Oncology, VU University Medical Center, Amsterdam The Netherlands.
³ INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.
⁴ Department of Medicine and Surgery, University of Parma, Parma, Italy.

Editorial

Alessandro Leonetti et al. Ann Transl Med. 2018 Dec.

. 2018 Dec;6(Suppl 2):S110.

doi: 10.21037/atm.2018.11.69.

Alessandro Leonetti^{1

2}, Francesco Facchinetti³, Marcello Tiseo^{1

4}

¹ Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
² Department of Medical Oncology, VU University Medical Center, Amsterdam The Netherlands.
³ INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.
⁴ Department of Medicine and Surgery, University of Parma, Parma, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: M Tiseo: Advisory boards and speakers’ fee for Astra-Zeneca. The other authors have no conflicts of interest to declare.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J. Reungwetwattana T, et al. J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. Online ahead of print. J Clin Oncol. 2018. PMID: 30153097

1. Lin JJ, Cardarella S, Lydon CA, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J. Thorac Oncol 2016;11:556-65. 10.1016/j.jtho.2015.12.103 - DOI - PMC - PubMed
1. Peters S, Bexelius C, Munk V, et al. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 2016;45:139-62. 10.1016/j.ctrv.2016.03.009 - DOI - PubMed
1. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108-11. 10.1016/j.lungcan.2015.01.020 - DOI - PMC - PubMed
1. Ge M, Zhuang Y, Zhou X, et al. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol 2017;135:413-8. 10.1007/s11060-017-2590-x - DOI - PubMed
1. Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012;70:399-405. 10.1007/s00280-012-1929-4 - DOI - PubMed